Stoke Therapeutics, Inc. Common Stock (STOK)

Price$30.01

Value ScoreD

Growth ScoreF

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-10.84%

Price vs S&P 500 (4W)-8.75%

VGM Score29.22

Market Capitalization$1.87B

All Metrics

P/CF (Annual)41.00x

Book Value / Share (Quarterly)$6.34

P/TBV (Annual)0.97x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)145.85%

Cash Flow / Share (Quarterly)$-2.37

Price vs S&P 500 (YTD)-13.61%

Net Profit Margin (TTM)-529.20%

EPS (TTM)$-2.83

10-Day Avg Trading Volume0.51M

EPS Excl Extra (TTM)$-2.83

EPS (Annual)$-0.12

ROI (Annual)-1.95%

Net Profit Margin (5Y Avg)-2289.09%

Cash / Share (Quarterly)$5.52

P/E Basic Excl Extra (TTM)46.10x

Revenue Growth QoQ (YoY)-96.07%

ROA (Last FY)-1.65%

Revenue Growth TTM (YoY)-83.20%

EBITD / Share (TTM)$-3.07

ROE (5Y Avg)-40.10%

Operating Margin (TTM)-577.46%

Cash Flow / Share (Annual)$0.76

P/B Ratio4.73x

P/B Ratio (Quarterly)5.13x

Net Income / Employee (Annual)$-40,500

EV / Revenue (TTM)53.41x

ROA (TTM)-42.27%

EV / EBITDA (TTM)59.61x

EPS Incl Extra (Annual)$-0.12

Current Ratio (Annual)5.28x

Quick Ratio (Quarterly)8.74x

3-Month Avg Trading Volume0.68M

52-Week Price Return175.83%

EV / Free Cash Flow (Annual)38.15x

P/E Incl Extra (TTM)46.10x

Revenue / Employee (TTM)$188,700

Tangible BV / Share (Quarterly)$3.91

P/S Ratio (Annual)10.13x

Asset Turnover (Annual)0.44x

52-Week High$40.22

Operating Margin (5Y Avg)-2353.28%

EPS Excl Extra (Annual)$-0.12

CapEx CAGR (5Y)-8.59%

26-Week Price Return-2.91%

Quick Ratio (Annual)5.13x

13-Week Price Return-13.39%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.99x

Enterprise Value$1.71B

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)-5.21%

Revenue / Employee (Annual)$1,084,800

Pretax Margin (Annual)-3.73%

Cash / Share (Annual)$4.83

3-Month Return Std Dev48.84%

Net Income / Employee (TTM)$-998,600

ROE (Last FY)-1.95%

EPS Basic Excl Extra (Annual)$-0.12

Receivables Turnover (TTM)37.67x

EV / Free Cash Flow (TTM)43.72x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.83

Receivables Turnover (Annual)34.46x

ROI (TTM)-48.84%

P/S Ratio (TTM)58.26x

Pretax Margin (5Y Avg)-2289.09%

Revenue / Share (Annual)$3.11

Tangible BV / Share (Annual)$4.69

Forward P/E3939.76x

Price vs S&P 500 (52W)151.46%

P/E Ratio (TTM)46.10x

Year-to-Date Return-5.45%

5-Day Price Return-1.51%

EPS Normalized (Annual)$-0.12

ROA (5Y Avg)-31.13%

Net Profit Margin (Annual)-3.73%

Month-to-Date Return-2.91%

Cash Flow / Share (TTM)$-2.37

EBITD / Share (Annual)$-0.32

Operating Margin (Annual)-11.16%

P/CF (TTM)44.93x

ROI (5Y Avg)-40.10%

P/E Excl Extra (TTM)46.10x

EPS Basic Excl Extra (TTM)$-2.83

P/TBV (Quarterly)1.04x

P/B Ratio (Annual)5.14x

Pretax Margin (TTM)-533.18%

Book Value / Share (Annual)$5.98

Price vs S&P 500 (13W)-21.65%

Beta1.19x

P/FCF (Annual)41.61x

Revenue / Share (TTM)$0.51

ROE (TTM)-48.84%

52-Week Low$10.63

vGradeD

gGradeF

mGradeB

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.79est. -0.84

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.39

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
STOKStoke Therapeutics, Inc. Common Stock	D	F	B	$30.01
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Stoke Therapeutics develops antisense oligonucleotides (ASOs) to treat genetic diseases through its proprietary TANGO platform, which restores protein expression in haploinsufficiency disorders. The company's lead candidate, zorevunersen, has demonstrated potential for disease modification in Dravet syndrome patients. Its pipeline focuses on mutation-agnostic treatments for rare genetic disorders affecting the central nervous system and eye.